These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 9313757

  • 1. High-dose intravenous insulin infusion versus intensive insulin treatment in newly diagnosed IDDM.
    Schnell O, Eisfelder B, Standl E, Ziegler AG.
    Diabetes; 1997 Oct; 46(10):1607-11. PubMed ID: 9313757
    [Abstract] [Full Text] [Related]

  • 2. Effects of nicotinamide and intravenous insulin therapy in newly diagnosed type 1 diabetes.
    Vidal J, Fernández-Balsells M, Sesmilo G, Aguilera E, Casamitjana R, Gomis R, Conget I.
    Diabetes Care; 2000 Mar; 23(3):360-4. PubMed ID: 10868866
    [Abstract] [Full Text] [Related]

  • 3. Vitamin E and nicotinamide have similar effects in maintaining residual beta cell function in recent onset insulin-dependent diabetes (the IMDIAB IV study).
    Pozzilli P, Visalli N, Cavallo MG, Signore A, Baroni MG, Buzzetti R, Fioriti E, Mesturino C, Fiori R, Romiti A, Giovannini C, Lucentini L, Matteoli MC, Crinò A, Teodonio C, Paci F, Amoretti R, Pisano L, Suraci C, Multari G, Suppa M, Sulli N, De Mattia G, Faldetta MR.
    Eur J Endocrinol; 1997 Sep; 137(3):234-9. PubMed ID: 9330586
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effect of bacille Calmette-Guérin vaccination on C-peptide secretion in children newly diagnosed with IDDM.
    Elliott JF, Marlin KL, Couch RM.
    Diabetes Care; 1998 Oct; 21(10):1691-3. PubMed ID: 9773732
    [Abstract] [Full Text] [Related]

  • 6. Beta-cell response to intravenous glucagon in African-American and Hispanic children with type 2 diabetes mellitus.
    Taha DR, Castells S, Umpaichitra V, Bastian W, Banerji MA.
    J Pediatr Endocrinol Metab; 2002 Jan; 15(1):59-67. PubMed ID: 11822582
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). The DCCT Research Group.
    J Clin Endocrinol Metab; 1987 Jul; 65(1):30-6. PubMed ID: 2884229
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function.
    Pampanelli S, Torlone E, Ialli C, Del Sindaco P, Ciofetta M, Lepore M, Bartocci L, Brunetti P, Bolli GB.
    Diabetes Care; 1995 Nov; 18(11):1452-9. PubMed ID: 8722069
    [Abstract] [Full Text] [Related]

  • 11. Homogeneity in pattern of decline of beta-cell function in IDDM. Prospective study of 204 consecutive cases followed for 7.4 yr.
    Snorgaard O, Lassen LH, Binder C.
    Diabetes Care; 1992 Aug; 15(8):1009-13. PubMed ID: 1505301
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group.
    Ann Intern Med; 1998 Apr 01; 128(7):517-23. PubMed ID: 9518395
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Soluble CD8 antigen, stimulated C-peptide and islet cell antibodies are predictors of insulin requirement in newly diagnosed patients with unclassifiable diabetes.
    Di Bonito P, De Bellis A, Capaldo B, Turco S, Corigliano G, Pace E, Bizzarro A.
    Acta Diabetol; 1996 Sep 01; 33(3):220-4. PubMed ID: 8904929
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Residual beta cell function in newly diagnosed type 1 diabetes after treatment with atorvastatin: the Randomized DIATOR Trial.
    Martin S, Herder C, Schloot NC, Koenig W, Heise T, Heinemann L, Kolb H, DIATOR Study Group.
    PLoS One; 2011 Mar 11; 6(3):e17554. PubMed ID: 21412424
    [Abstract] [Full Text] [Related]

  • 18. Proinsulin immunoreactivity in recent-onset IDDM: the significance of insulin antibodies and insulin autoantibodies.
    Snorgaard O, Kjems LL, Røder ME, Hartling SG, Dinesen B, Binder C.
    Diabetes Care; 1996 Feb 11; 19(2):146-50. PubMed ID: 8718435
    [Abstract] [Full Text] [Related]

  • 19. Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM.
    Dupre J, Behme MT, Hramiak IM, McFarlane P, Williamson MP, Zabel P, McDonald TJ.
    Diabetes; 1995 Jun 11; 44(6):626-30. PubMed ID: 7789625
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.